CNS Pharmaceuticals(CNSP) - 2024 Q1 - Quarterly Results

Form 8-K Filing Details This section provides essential information regarding the Form 8-K filing, including registrant details and report date Registrant and Filing Information This section identifies CNS Pharmaceuticals, Inc. as the registrant, details its incorporation state (Nevada), and confirms its status as an emerging growth company. The report date is May 16, 2024 - Registrant: CNS Pharmaceuticals, Inc.[1] - Incorporation State: Nevada[1] - Emerging Growth Company: Yes[3] - Date of Report (earliest event reported): May 16, 2024[1] Securities Registration The company's common stock is registered on The NASDAQ Stock Market LLC under the trading symbol CNSP Securities Registered Pursuant to Section 12(b) of the Act | Title of each class | Trading Symbols(s) | Name of each exchange on which registered | | :------------------ | :----------------- | :---------------------------------------- | | Common stock, par value $0.001 per share | CNSP | The NASDAQ Stock Market LLC | Item 2.02 Results of Operations and Financial Condition This section details the announcement of the company's financial results and operational highlights for the first quarter Announcement of Financial Results CNS Pharmaceuticals, Inc. issued a press release on May 16, 2024, announcing its financial results for the first quarter ended March 31, 2024, along with recent operational highlights. This press release is incorporated by reference as Exhibit 99.1 - Company issued a press release on May 16, 2024[5] - The press release announced financial results for Q1 ended March 31, 2024, and recent operational highlights[5] - The press release is attached as Exhibit 99.1 and incorporated by reference[5] Item 9.01 Financial Statements and Exhibits This section lists all financial statements and exhibits filed as part of the Form 8-K report Exhibits Filed This section lists the exhibits filed with the Form 8-K, including the press release (Exhibit 99.1) detailing Q1 2024 results and the Cover page Interactive Data File (Exhibit 104) List of Exhibits | Exhibit No. | Exhibit Description | | :---------- | :---------------------------------------------------------- | | 99.1 | Press release dated May 16, 2024 | | 104 | Cover page Interactive Data File (embedded within the Inline XBRL document) | Signature This section confirms the official signing and submission of the Form 8-K report Report Signatory The report was duly signed on behalf of CNS Pharmaceuticals, Inc. by Chris Downs, Chief Financial Officer, on May 16, 2024 - Report signed by Chris Downs, Chief Financial Officer[10] - Signature Date: May 16, 2024[10]